Arcus Biosciences up after FDA's 'orphan drug' tag for pancreatic cancer treatment

Arcus Biosciences

10/07/2025 16:39

** Shares of drug developer Arcus Biosciences RCUS.N rise 1.9% to $9.51

** Company says it received an "orphan drug" designation from the U.S. FDA to its experimental treatment, quemliclustat, to treat pancreatic cancer

** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.

** Company says it is currently testing the drug in a late-stage study and expects to enroll participants by the end of this year

** Including session moves, stock down 35.9% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))